In recent weeks, Eli Lilly has been flexing its social media muscles in an effort reach out to journalists on the popular platforms of Facebook and Twitter.
Facebook CEO and founder Mark Zuckerberg has sought out a top Genentech alum for the social media giant's board of directors.
Over the weekend cancer researchers and tech aces from Google and other companies teamed up to quickly blueprint a mobile game to advance research of tumor genes. It's one of the latest in a spate of missions to crowdsource tech talent and employ average citizens to take on scientific challenges.
Playing video games on mobile devices could help researchers solve riddles in mountains of genetic tumor data. And Cancer Research UK has enlisted programming talent from Amazon Web Services, Facebook and Google to help craft a mobile game to make video game players into "citizen scientists."
Pharma now has another hint about FDA's attitudes toward social media. In a recent warning letter to supplement maker AMARC Enterprises, FDA took issue with the company's use of Facebook's "Like" feature. Apparently, the company "Liked" a questionable user testimonial--and the agency didn't like it.
Americans are more likely to know the names of Tom Brady's kids than the names of the last couple of scientists to win Nobel prizes in medicine. That's because our fame-infatuated culture...
With more than 1 billion users plugged in, Facebook has huge potential to have a real impact on science and public health, beyond just a marketing platform for biotech and pharma companies.
Boehringer Ingelheim has rolled out a new blog as the German drugmaker travels yet another avenue of social media. The company has tapped just about every major social media platform and in September launched the online pharma game "Syrum" on Facebook.
Attention pharma workers reading this story on an iPad with plans to tweet it: You're not alone in your consumption of mobile tech and social media.
But the survey of 356 patients showed that 47% of them had a negative opinion of pharma companies in general compared with 30% of advocates with overall favorable views on drugmakers.